Skip to the page

Data / Drug companies / Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc.: 37 products in the FDA NDC directory, labeler code 64764

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Takeda Pharmaceuticals America, Inc. (labeler code 64764) lists 37 products in the FDA National Drug Code Directory, covering 16 finished drugs by generic name. By type: 35 prescription drugs, 2 bulk ingredients. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 20, 2025.

The request: Watch Takeda Pharmaceuticals America, Inc. (FDA labeler code 64764): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
64764
Products in commercial distribution
37
Packages
106
Finished drugs by generic name
16
Prescription products
35
Over the counter products
0
Flagged as original packager
33 of 33 products that carry the flag
Started marketing in the last 12 months
0
Products with a marketing end date set
2
Earliest marketing start
May 10, 1995
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)3081.1%
Biologics (BLA)513.5%
Bulk ingredients25.4%

Products by type

TypeProductsShare
Prescription drugs3594.6%
Bulk ingredients25.4%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet, film coated1437.8%
Tablet718.9%
Capsule, delayed release38.1%
Liquid25.4%
Capsule, gelatin coated25.4%
Injection, solution25.4%
Kit25.4%
Tablet, orally disintegrating, delayed release25.4%
Tablet, coated12.7%
Suspension12.7%
Injection, powder, lyophilized, for solution12.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Vedolizumab64764-065LiquidBulk ingredientsOctober 20, 2025
Vedolizumab64764-075LiquidBulk ingredientsAugust 26, 2024
Eohilia64764-105SuspensionNew drug applications (NDA)February 9, 2024
Adzynma64764-145KitBiologics (BLA)November 9, 2023
Adzynma64764-140KitBiologics (BLA)November 9, 2023
ENTYVIO Pen64764-108Injection, solutionBiologics (BLA)September 27, 2023
Entyvio64764-107Injection, solutionBiologics (BLA)September 27, 2023
Livtencity64764-800Tablet, coatedNew drug applications (NDA)November 23, 2021
Entyvio64764-300Injection, powder, lyophilized, for solutionBiologics (BLA)May 20, 2014
Trintellix64764-750Tablet, film coatedNew drug applications (NDA)October 2, 2013
Trintellix64764-730Tablet, film coatedNew drug applications (NDA)October 2, 2013
Trintellix64764-720Tablet, film coatedNew drug applications (NDA)October 2, 2013
Nesina64764-625Tablet, film coatedNew drug applications (NDA)January 25, 2013
Kazano64764-337Tablet, film coatedNew drug applications (NDA)January 25, 2013
Kazano64764-335Tablet, film coatedNew drug applications (NDA)January 25, 2013
Oseni64764-254Tablet, film coatedNew drug applications (NDA)January 25, 2013
Oseni64764-253Tablet, film coatedNew drug applications (NDA)January 25, 2013
Oseni64764-251Tablet, film coatedNew drug applications (NDA)January 25, 2013
Nesina64764-250Tablet, film coatedNew drug applications (NDA)January 25, 2013
Nesina64764-125Tablet, film coatedNew drug applications (NDA)January 25, 2013
Oseni64764-123Tablet, film coatedNew drug applications (NDA)January 25, 2013
Dexilant64764-175Capsule, delayed releaseNew drug applications (NDA)April 12, 2010
Dexilant64764-171Capsule, delayed releaseNew drug applications (NDA)April 12, 2010
Uloric64764-918TabletNew drug applications (NDA)February 13, 2009
Uloric64764-677TabletNew drug applications (NDA)February 13, 2009

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.